Local delivery of an antithrombin inhibits platelet-dependent thrombosis.
- 1 October 1994
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 90 (4) , 1951-1955
- https://doi.org/10.1161/01.cir.90.4.1951
Abstract
BACKGROUND Platelet-dependent thrombosis can be effectively inhibited by intravenous administration of direct thrombin antagonists. However, an increased propensity for abnormal bleeding has been associated with systemic administration of these agents. The goal of this study was to determine whether local delivery of a potent thrombin inhibitor, D-Phe-L-Pro-L-Arg chloromethyl ketone (PPACK), could inhibit platelet-dependent thrombosis without altering systemic hemostatic function. METHODS AND RESULTS Thrombus formation was measured by quantitative imaging of 111In-labeled platelet deposition on segments of thrombogenic vascular graft interposed in arteriovenous shunts in a porcine model. Intravenous administration of PPACK inhibited platelet deposition at a dose of 12.5 micrograms/kg per minute, which was associated with significant prolongations of both template bleeding times and activated partial thromboplastin times. By contrast, local infusion of PPACK at a dose of 0.02 micrograms/kg per minute (ie, a 600-fold smaller dose) into the fluid boundary layer at the interface between flowing blood and the thrombogenic segment produced equivalent inhibition of platelet deposition without prolonging either the bleeding time or the activated partial thromboplastin time. In addition, static exposure of a mural thrombus to solutions of PPACK at concentrations > or = 2.5 mg/mL for 15 minutes produced sustained inhibition of platelet-dependent thrombosis with no change in hemostatic measurements. CONCLUSIONS These results indicate that local delivery of the direct antithrombin PPACK, by either boundary layer infusion or static application techniques, effectively inhibits platelet-dependent thrombosis at doses that are several orders of magnitude less than the systemic dose required for an equivalent antithrombotic effect. In contrast to the systemic administration of PPACK, local delivery produced maximal inhibition of thrombosis without alterations in hemostasis.Keywords
This publication has 12 references indexed in Scilit:
- In vitro and in vivo evaluation of the site-specific administration of d-phenylalanyl-l-prolyl-l-arginyl chloromethyl ketone (PPACK): a powerful thrombin inhibitorJournal of Controlled Release, 1993
- Angioscopic Evaluation of Coronary-Artery Thrombi in Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activationCell, 1991
- Heparin-resistant thrombus formation by endovascular stents in baboons. Interruption by a synthetic antithrombin.Circulation, 1990
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990
- Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.Proceedings of the National Academy of Sciences, 1988
- Localization of the binding site on fibrin for the secondary binding site of thrombinBiochemistry, 1988
- Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1985
- Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.Journal of Clinical Investigation, 1985
- Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.Circulation, 1985